INmune Bio reports positive MRI results in Alzheimer's trial

June 2, 2026 8:00 AM

INmune Bio Inc. (NASDAQ: INMB) announced results from MRI imaging analyses of its Phase 2 MINDFuL clinical trial testing XPro1595 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found